More recently, phase 3 Keynote 189 and Keynote 407 trials, in non-squamous and squamous advanced NSCLC, respectively, reported significantly improved overall survival (OS) and progression-free survival (PFS) with manageable toxicity when adding pembrolizumab to first-line histology driven chemotherapy, irrespective of PD-L1 expression [3,4]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.